Antacids Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The Antacids market size was estimated at USD 7.3 billion in 2023 and is projected to reach USD 10.30 billion in 2030 at a CAGR of 5.04% during the forecast period 2023-2030.

Antacids are over-the-counter medications commonly used to alleviate symptoms of heartburn, acid reflux, and indigestion. They work by neutralizing excess stomach acid, which can cause discomfort and irritation in the oesophagus and stomach. Antacids contain compounds such as aluminium hydroxide, magnesium hydroxide, calcium carbonate, or sodium bicarbonate, which react with stomach acid to form water and salt, thereby reducing acidity. They provide relatively rapid relief from symptoms like burning sensation in the chest or throat. However, it’s important to note that antacids are not a long-term solution for chronic conditions like gastroesophageal reflux disease (GERD) or ulcers.

The market is being driven by various factors. Firstly, the rising awareness about GERD is expected to boost market growth. Moreover, the rising geriatric population is also contributing to the growth of the market as more that 65% of the geriatric population suffers from acid reflux. In addition, surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. he rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities. 

However, the antacids market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence. Moreover, Antacids, especially those containing aluminium or magnesium, can have side effects such as constipation or diarrhoea Additionally, long-term use of certain antacids has been associated with potential health risks, such as kidney problems. These safety concerns can affect consumer confidence and lead to a decline in sales.

COVID-19 has had a significant impact on the growth of the market. People have been less likely to go to the doctor or hospital due to the fear of contracting COVID-19. Moreover, many medical settings were closed or had limited their services due to the pandemic.

Delvens Industry Expert's Standpoint

The Antacids market is expected to grow during the forecast period. This growth can be attributed to various factors. Firstly, acid reflux disease is a common condition that causes heartburn and other symptoms. The prevalence of acid reflux disease is increasing which is driving the demand for antacids. Moreover, there is an increasing awareness of good oral health. This is driving the demand for antacids, as they can be used to treat heartburn and other conditions that can damage teeth and gums. In addition, OTC medications are becoming increasingly popular, as they are more convenient and affordable than prescription medications. This is also expected to drive the demand for antacids. However, antacids can have side effects such as constipation and diarrhoea. This can deter some people from using antacids.

Market Portfolio

Key Findings

• Based on type, the market is segmented into sodium antacids, calcium antacids, magnesium antacids aluminium antacids, others. Sodium antacids dominated the market in the segment. This is because sodium antacids are the most common type of antacid. They work by neutralizing stomach acid. Sodium antacids include Tums, Rolaids, and Maalox.
   
• Based on indication, the market is bifurcated into gastroesophageal reflux disease, heartburn, indigestion, others. Heartburn dominated the market in this segment as it is the most common indication for antacids. It is caused by the stomach acid backing up into the oesophagus. Antacids work by neutralizing stomach acid, which can help to relieve heartburn.
   
• Based on dosage form, the market is segmented into tablets, liquid, others. The presence of a variety of chewable tablets in the market with different flavours that help to improve patient adherence to the medication is expected to contribute to the growth of the segment.
   
• Based on end users, the market is segmented into hospitals, homecare, speciality centres, others. Hospitals dominated the market in this segment. This is due to the fact that they are the primary providers of care for patients who are being treated for acid reflux disease or other conditions that require antacids.
   
• Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy. Retail pharmacies dominated the market in this segment as they sell over-the-counter (OTC) antacids, as well as prescription antacids.

• Based on region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America. North America is expected to dominate the market in the forecast period. This is due to the growing geriatric population and lifestyle changes leading to gastrointestinal problems among the American population.

Regional Analysis

North America to Dominate the Market

• North America is estimated to account for the largest market share during the forecast period. This is due to the growing geriatric population and lifestyle changes leading to gastrointestinal problems among the American population.
   
• Moreover, the growing trend toward self-medication in North American countries such as the United States is increasing the demand for over-the-counter digestive products, such as antacids.

Competitive Landscape

• Aurobindo Pharma
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Cipla Inc
• Dr. Reddy’s Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi AG
• GSK Plc.
• Hikma Pharmaceuticals PLC
• Lupin
• Mylan N.V.
• Novartis AG
• Pfizer Inc
• Procter & Gamble
• Reckitt Benckiser Group PLC
• Sanofi
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd.

Recent Developments

• In February 2022, GSK started an independent consumer healthcare company called Haleon.
   
• In June 2022, Zydus Lifesciences received final approval from the United States Food and Drug Administration (FDA) to market Famotidine tablets in the strengths of 20 mg and 40 mg. Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Antacids Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope